Bioxcel Therapeutics Soars 11.11% on Positive Drug Study

Bioxcel Therapeutics' stock surged 11.11% in pre-market trading on August 6, 2025, driven by positive news surrounding its drug candidate BXCL501.

Bioxcel Therapeutics recently published a study in Frontiers in Pharmacology, highlighting the significant reduction in stress-induced behaviors demonstrated by dexmedetomidine, the active ingredient in BXCL501. This finding suggests potential applications for BXCL501 in treating chronic psychiatric conditions, which has garnered investor interest and contributed to the stock's upward momentum.

The study further revealed that dexmedetomidine exhibited higher potency compared to other alpha2-adrenergic receptor agonists, effectively mitigating responses to both acute and chronic stress. This enhanced efficacy has bolstered confidence in the drug's therapeutic potential, driving the stock's pre-market rally.